Pharmosa Biopharm Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	668.42	631.23	749.44	974.06	672.51	461.46
Short-Term Investments	200	500	869	-	-	-
Cash & Short-Term Investments	868.42	1,131	1,618	974.06	672.51	461.46
Cash Growth	-39.68%	-30.10%	66.16%	44.84%	45.73%	11.32%
Accounts Receivable	2.05	2.01	4.65	-	-	-
Other Receivables	11.41	6.91	6.69	1.47	0.29	0.31
Receivables	13.46	8.92	11.34	1.47	0.29	0.31
Inventory	24.08	19.81	24.74	21.91	-	-
Prepaid Expenses	47.39	42.93	27.22	12.67	11.65	14.18
Other Current Assets	-	1.46	-	-	-	0.02
Total Current Assets	953.35	1,204	1,682	1,010	684.45	475.96
Property, Plant & Equipment	582.23	458.67	315.06	180.61	30.12	33.44
Long-Term Investments	71.37	72.37	73.26	71.22	65.69	61.6
Other Intangible Assets	0.89	0.99	0.66	0.09	0.15	0.18
Other Long-Term Assets	10.74	12.15	92.88	71.62	18.95	15.19
Total Assets	1,619	1,749	2,164	1,334	799.37	586.37
Accounts Payable	0.9	8.13	0.68	0.59	-	-
Accrued Expenses	-	61.04	61.51	33.24	12.28	11.66
Current Portion of Long-Term Debt	-	-	-	1.26	3.52	8.43
Current Portion of Leases	22.08	18.6	17.98	24.69	7.19	6.8
Current Unearned Revenue	-	-	6.89	-	-	-
Other Current Liabilities	29.7	11.69	29.07	17.8	4.77	6.19
Total Current Liabilities	52.68	99.47	116.13	77.58	27.77	33.07
Long-Term Debt	-	-	-	1.19	2.45	5.96
Long-Term Leases	90.46	81.01	99.62	117.23	8.04	15.9
Long-Term Unearned Revenue	4.82	4.82	4.82	-	-	-
Other Long-Term Liabilities	5.32	5.27	5.1	-	-	-
Total Liabilities	153.28	190.57	225.66	195.99	38.25	54.93
Common Stock	645.76	645.76	645.43	586.02	554.67	489.24
Additional Paid-In Capital	-	-	-	531.34	1,180	-
Retained Earnings	-465.34	-371.18	-146.37	20.28	-973.44	-706.94
Comprehensive Income & Other	1,285	1,283	1,439	0.01	0.01	749.13
Shareholders' Equity	1,465	1,558	1,938	1,138	761.12	531.44
Total Liabilities & Equity	1,619	1,749	2,164	1,334	799.37	586.37
Total Debt	112.53	99.61	117.6	144.37	21.19	37.09
Net Cash (Debt)	755.89	1,032	1,501	829.69	651.32	424.37
Net Cash Growth	-43.02%	-31.26%	80.89%	27.39%	53.48%	46.28%
Net Cash Per Share	5.86	7.99	11.87	7.32	6.61	5.00
Filing Date Shares Outstanding	128.99	129.15	129.09	117.2	110.93	97.85
Total Common Shares Outstanding	128.99	129.15	129.09	117.2	110.93	97.85
Working Capital	900.67	1,105	1,566	932.53	656.68	442.89
Book Value Per Share	11.36	12.06	15.01	9.71	6.86	5.43
Tangible Book Value	1,464	1,557	1,937	1,138	760.97	531.25
Tangible Book Value Per Share	11.35	12.06	15.01	9.71	6.86	5.43
Machinery	-	117.12	68.34	27.11	26.37	17.05
Construction In Progress	-	268.02	134.42	-	-	-
Leasehold Improvements	-	30.25	28.85	35.61	-	-